Sayre Therapeutics, a super-speciality pharma company, on Monday said it has raised $8 million across two rounds of funding from Accel Partners and Aarin Capital.

The company, which has a portfolio of oncology, interventional oncology and immunology drugs, drug delivery devices and diagnostics, has also raised $1 million in venture-debt from InnoVen Capital, it said in a statement.